Immunisation to protect against transmissible cancers in Tasmanian devils. This project aims to identify the immune escape mechanisms that the transmissible cancers, Devil Facial Tumour Disease (DFTD) use to avoid being killed by the immune system. Since the discovery of the second transmissible cancer (DFT2) mystery surrounds whether the devils immune system can respond to this cancer, hence this project will investigate the immune response to DFT2. The final aims are to develop a vaccine with ....Immunisation to protect against transmissible cancers in Tasmanian devils. This project aims to identify the immune escape mechanisms that the transmissible cancers, Devil Facial Tumour Disease (DFTD) use to avoid being killed by the immune system. Since the discovery of the second transmissible cancer (DFT2) mystery surrounds whether the devils immune system can respond to this cancer, hence this project will investigate the immune response to DFT2. The final aims are to develop a vaccine with the potential to protect healthy devils and cure devils with DFTD.Read moreRead less
Understanding gender differences in pain: Cellular therapies for animal pain. Understanding gender differences in pain: Cellular therapies for animal pain. This project aims to relieve chronic pain in animals and lay the foundations for future human therapies, using molecular assays, cell technologies and immune/hormonal pain generators. Chronic pain affects females more than males. Establishing the fundamental mechanism in pain, the role of immune signalling and molecular mediators will enable ....Understanding gender differences in pain: Cellular therapies for animal pain. Understanding gender differences in pain: Cellular therapies for animal pain. This project aims to relieve chronic pain in animals and lay the foundations for future human therapies, using molecular assays, cell technologies and immune/hormonal pain generators. Chronic pain affects females more than males. Establishing the fundamental mechanism in pain, the role of immune signalling and molecular mediators will enable true pain-modifying treatments that address pivotal triggers in both genders. This project will then use specially selected stem cells separately targeting arthritic male and female pain and demonstrate novel veterinary chronic pain treatments. Expected outcomes are more effective gender-targeted treatments of pain and the realisation of economic value of molecular assays and cell technologies.Read moreRead less
Superbugs and veterinary drugs: are multidrug-resistant zoonotic pathogens residing in Australian animals? Antibiotic resistance is a growing problem affecting human health that is now emerging in animals and veterinary hospitals. This project will integrate surveillance with novel treatments and preventatives to develop effective strategies to limit the impact of resistant bacteria to animal health and prevent transfer between humans and animals.
Discovery Early Career Researcher Award - Grant ID: DE120100390
Funder
Australian Research Council
Funding Amount
$375,000.00
Summary
Characterisation of collagenous lectins and their roles in ovine infectious diseases. Specific proteins involved in immunity against infections will be studied in sheep to enhance their immune response against specific infections, such as ovine Johne's disease and footrot. This may lead to selective breeding of sheep that are more resistant to disease, minimising production losses and use of medications.
Development of a vaccine to protect koalas against koala retrovirus (KoRV). This project aims to develop a vaccine against koala retrovirus (KoRV) to arrest the increasing loss of animals due to this infection. Along with Chlamydia, KoRV threatens the long-term survival of the koala. KoRV infects over 95 per cent of Australia’s koalas and has been strongly linked to lymphoma and leukemia. Although quarantine and antiretroviral drug treatment are possible control measures, they are impractical in ....Development of a vaccine to protect koalas against koala retrovirus (KoRV). This project aims to develop a vaccine against koala retrovirus (KoRV) to arrest the increasing loss of animals due to this infection. Along with Chlamydia, KoRV threatens the long-term survival of the koala. KoRV infects over 95 per cent of Australia’s koalas and has been strongly linked to lymphoma and leukemia. Although quarantine and antiretroviral drug treatment are possible control measures, they are impractical in the wild, leaving vaccination as the only realistic option. This is valuable for both wild and captive koalas; zoos report high animal losses due to KoRV-associated lymphoma. The main outcome will be a KoRV vaccine which can be combined with a Chlamydia vaccine which is being developed in parallel.Read moreRead less